New Alzheimer’s Pill Fails to Deliver Major Benefit

Here’s a breakdown of the neurologists’ concerns about the Alzheimer’s pill, as expressed in the provided text:

* ​ Dr.Clifford Segil (Providence ‍saint john’s Health Center):

⁤ * “Nominally” Notable results: He criticizes the ‍researchers’​ use of the term “nominally” significant to describe ⁣the 52% ‌cognitive decline improvement. He‍ argues that “nominally” means “in name only” and rarely translates to real positive effects in clinical practise.
* Dr. Amit Sachdev (Michigan State University):

⁢ * Doesn’t Remove Existing Plaques: The pill doesn’t address amyloid plaques already present in the brain,which he ‍believes disrupt ⁣brain function. Simply ⁣slowing new plaque formation may not be ‌enough.
* Trial Length: The 78-week trial might potentially be insufficient to accurately measure ‍the effects of the ‍drug, as Alzheimer’s frequently enough progresses slowly.
* Population Variability: The drug’s effects could vary significantly across different patient populations.
* Dr. Schrag:

⁤ * Weak Data/Subgroup Analysis: He dismisses the results as⁣ akin to “reading tea leaves,” suggesting ​the positive findings were derived from analyzing a very specific subgroup of patients.
* No Further Inquiry Needed: He believes the​ data doesn’t warrant further⁢ investigation of valiltramiprosate, suggesting the biology isn’t promising.

In essence, the neurologists are⁢ skeptical of the drug’s effectiveness, questioning the validity of the reported benefits ​and highlighting potential limitations in the trial design and the drug’s mechanism of action.